As current treatment strategies for diabetic nephropathy, namely intensive control of glucose levels and blood pressure, cannot fully prevent the development and progression of the disease, new therapeutic approaches are urgently needed. Here, Muskiet and colleagues discuss the status of currently available incretin-based agents—agonists of glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase 4—and their potential renoprotective effects in patients with type 2 diabetes mellitus.
- Marcel H. A. Muskiet
- Mark M. Smits
- Michaela Diamant
